Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
troyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from troyrecord.com Daily Mail and Mail on Sunday newspapers.
Lavie Bio Provides Product Pipeline Update for 2020
USA - English
News provided by
Share this article
Share this article
REHOVOT, Israel, Dec. 29, 2020 /PRNewswire/ Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.
Lavie Bio Logo
Evogene Logo Our commitment and main focus at Lavie Bio is to develop novel microbiome based ag-biological products, bio-pesticides & bio-stimulants that address the dire need for new tools to increase agriculture productivity while improving sustainability and food quality. 2020 was a remarkable year in our journey to achieve these targets, stated